Patients and families are at the heart of every rare disease journey. Guided by their experiences, we are committed to transforming care in rare disease and advancing meaningful innovation where unmet needs remain.
Across rare disease, patients continue to navigate serious conditions with few effective treatments. Hear from Renee Gala, President and CEO, on how we are sharpening our strategic focus to drive innovation and strengthen our commitment to delivering meaningful impact for patients and their families. For families facing diffuse midline glioma, rapid progression and scarce options have long defined the journey. Hear how following the biology, learning from outliers, and uniting researchers, clinicians, advocates, and families led to meaningful progress and a new therapeutic option for patients with H3 K27M‑mutant disease. Jazz has a longstanding commitment to sleep medicine through vital partnerships with notable organizations in the community. Collaborations with patient advocacy groups are crucial for understanding patient needs, raising awareness of comorbidities through educational resources and improving comprehensive care for people living with narcolepsy or idiopathic hypersomnia.